HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SNGX
Soligenix, Inc.
There isn't enough reported data to score SNGX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SNGX PE Valuation
SNGX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SNGX Forward outlook
There aren't enough analyst estimates for SNGX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
SNGX has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus SNGX down 116%.
SNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$31.84 | +$52.16 |
| Q2 2023 | -$48.48 | +$37.92 |
| Q1 2023 | -$58.72 | +$25.28 |
| Q4 2022 | -$76.96 | -$2.56 |
| Q3 2022 | -$84.00 | +$2.40 |
| Q2 2022 | -$86.40 | -$7.20 |
| Q1 2022 | -$84.00 | +$7.20 |
| Q4 2021 | -$74.40 | +$79.20 |
SNGX is still losing money, but far less than before: $5.17 per share over the past year, against $170.40 at its worst in early 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for SNGX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $2.3K | -99% |
| Q1 2024 | $117K | -54% |
| Q4 2023 | $244.8K | -33% |
| Q3 2023 | $130.4K | -21% |
| Q2 2023 | $206.9K | -9.5% |
| Q1 2023 | $257.2K | +37% |
| Q4 2022 | $366.1K | +33% |
| Q3 2022 | $166.1K | -11% |
SNGX's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -74495% | -73707 points |
| Q1 2024 | -1809% | -973 points |
| Q4 2023 | -873% | +102 points |
| Q3 2023 | -1364% | +491 points |
| Q2 2023 | -788% | +697 points |
| Q1 2023 | -836% | +1398 points |
| Q4 2022 | -975% | +665 points |
| Q3 2022 | -1855% | -42 points |
SNGX's operating margin was −74495% last quarter, down 73707 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
SNGX has the stronger cash trend. Its trailing FCF is up 6.1% versus its history, compared with HIMS at down 84%.
SNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.4M | -$510.7K |
| Q4 2025 | -$2.7M | -$514.2K |
| Q3 2025 | -$2.9M | -$22.8K |
| Q1 2025 | -$1.8M | -$504.5K |
| Q4 2024 | -$2.2M | -$404.6K |
| Q3 2024 | -$2.9M | -$224.1K |
| Q2 2024 | -$1.9M | +$5.5K |
| Q1 2024 | -$1.3M | +$823.8K |
SNGX has burned cash in almost every quarter: −$10M over the past year, against −$8M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SNGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SNGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +39% | +6.2M shares |
| 1 year | +576% | +18.9M shares |
| 3 years | +12241% | +22M shares |
| 5 years | +17874% | +22M shares |
SNGX has 22M diluted shares, up 576% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SNGX Net Leverage
SNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 17.2 | Oversold |
SNGX's weekly RSI is 35 (neutral) and its Stochastic is 17 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SNGX PE vs Healthcare Sector
SNGX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.36 | 11% below |
| 20 week MA | $0.37 | 14% below |
| 50 week MA | $0.77 | 58% below |
| 100 week MA | $1.44 | 78% below |
| 200 week MA | $8.25 | 96% below |
SNGX is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SNGX on returns for 2026, with the stronger performance.
SNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $340.8 | $321.6 | -5.6% |
| 2021 | $321.6 | $184.3 | -43% |
| 2022 | $184.3 | $154.9 | -16% |
| 2023 | $154.9 | $12.1 | -92% |
| 2024 | $12.1 | $2.89 | -76% |
| 2025 | $2.89 | $1.37 | -53% |
| 2026 YTD | $1.37 | $0.32 | -77% |
SNGX has finished every year since 2020 lower, and it's down 77% so far in 2026.